QUOTE AND NEWS
StreetInsider.com  Sep 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Halozyme+Therapeutics+%28HALO%29+Reports+Removal+of+FDA+Clinical+Hold+on+PEGPH20+Phase+1b2/9843773.html for the full story.
Benzinga  Sep 18  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is...
SeekingAlpha  Sep 16  Comment 
By Samreen Agha: The shares of Halozyme Therapeutics, Inc. (HALO) were up almost 7.5% afterhours following the news of FDA's approval of Halozyme and Baxter International's (BAX) HyQvia, on September 13, 2014. Come Monday the shares came tumbling...
SeekingAlpha  Sep 15  Comment 
By Emerging Equities: Halozyme Therapeutics Inc. (NASDAQ:HALO) recently announced that the FDA granted a Fast Track Designation for its PEGPH20 program in metastatic pancreatic cancer. It is still too early to speculate on a potential approval,...
FierceBiotech  Sep 15  Comment 
Two years after safety concerns torpedoed their first pitch, partners Baxter and Halozyme Therapeutics have locked up FDA approval for HyQvia, a treatment for immunodeficiency.
StreetInsider.com  Sep 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FDA+Approves+Baxter%E2%80%99s+HYQVIA+for+Primary+Immunodeficiency+%28BAX%29+%28HALO%29/9830700.html for the full story.
newratings.com  Sep 13  Comment 
DEERFIELD (dpa-AFX) - Baxter International Inc (BAX) and Halozyme Therapeutics Inc (HALO) said Friday the United States Food and Drug Administration approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency...
SeekingAlpha  Sep 4  Comment 
By Mark Kroenke: Antibiotic resistance is a problem. There is no question that novel compounds are needed, and Congress has attempted to jump start development of new anti-infectives by passing the GAIN act which went into effect October 1st,...
Benzinga  Sep 3  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase)...
SeekingAlpha  Aug 11  Comment 
Halozyme Therapeutics (NASDAQ:HALO) Q2 2014 Earnings Call August 11, 2014 4:30 pm ET Executives Schond Greenway - Helen I. Torley - Chief Executive Officer, President and Director David A. Ramsay - Chief Financial Officer,...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki